Mechanical ventilation during critical care can cause structural and functional disturbances in the lung with subsequent release of proinflammatory mediators, termed ventilator-induced lung injury (VILI). VILI progressively provokes decreased efficiency of gas exchange with subsequent hypoxic pulmonary vasoconstriction leading to cardiopulmonary alterations, such as pulmonary hypertension and right heart failure. We therefore aimed to evaluate whether inhalation therapy with levosimendan, a calcium-sensitizer with pulmonary vasodilating properties, could attenuate VILI and improve short-term survival in a rat experimental model.
Experimental animal model.
Forty male Sprague-Dawley rats.
Rats were randomly treated as follows (n = 8, each group): 1) inhalation of the solvent only before induction of VILI, no further intervention; 2) inhalation of 240 μg of levosimendan before VILI induction; 3) inhalation of 24 μg of levosimendan before VILI induction; 4) intravenous administration of 24 μg/kg levosimendan before VILI induction; 5) control group with surgical preparation only. All groups were observed for 4 hrs.
After 4 hrs following induction of VILI, levels of interleukin-1β and macrophage inflammatory protein-2 in plasma and bronchoalveolar lavage fluid were analyzed by enzyme-linked immunosorbent assay. Nitric oxide release from alveolar macrophages was measured by Griess assay. Content of matrix metalloproteinase-2 and matrix metalloproteinase-9 in bronchoalveolar lavage fluid was analyzed by gelatin zymography. Inhalation of 240 μg of levosimendan significantly improved survival after 4 hrs and mean arterial blood pressure compared with VILI only. Additionally, inhalation of 240 μg and infusion of 24 μg/kg levosimendan significantly reduced the release of interleukin-1β, the nitric oxide release from alveolar macrophages, macrophage inflammatory protein-2 in plasma, and the macrophage inflammatory protein-2 and matrix metalloproteinase-9 content in bronchoalveolar lavage fluid compared with VILI only.
Our study demonstrates that prophylactic inhalation of 240 μg of levosimendan improves survival and reduces release of inflammatory mediators in our experimental model of VILI. This might affect the clinical prophylaxis and treatment of VILI.
From the Department of Anesthesiology, Intensive Care and Pain Therapy, University Hospital of Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Supported by departmental funding.
The authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com